Date: January 12th, 2014 12:25 AM Author: salmon cuck faggot firefighter
Aegis looks for Evoke Pharma to increase sevenfold
Aegis starts Evoke Pharma (EVOK) at Buy with a $60 target (that represents upside of ~636%).Analyst Raghuram Selvaraju likes the regulatory chances for EVK-001 (intranasal metoclopramide)."Since the compound in question is already approved for the same indication in which Evoke is aiming to test it, this program seems a low-risk proposition," Selvaraju says.Shares +54% premarket